Alpha Tau Medical Stock (NASDAQ:DRTS)

Forecast Ownership Financials Chart

Previous Close

$2.56

52W Range

$1.75 - $4.39

50D Avg

$2.74

200D Avg

$2.62

Market Cap

$176.91M

Avg Vol (3M)

$69.66K

Beta

0.93

Div Yield

DRTS Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

125

IPO Date

Mar 08, 2021

Website

DRTS Performance

DRTS Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-35.68M	$-32.14M	$-13.79M
Net Income	$-29.16M	$-33.76M	$-27.27M
EBITDA	$-34.61M	$-32.14M	$-13.79M
Basic EPS	$-0.42	$-0.53	$-0.40
Diluted EPS	$-0.42	$-0.53	$-0.40

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
CSBR	Champions Oncology, Inc.
HCWB	HCW Biologics Inc.
MOLN	Molecular Partners AG
OCUL	Ocular Therapeutix, Inc.
MNOV	MediciNova, Inc.
GNFT	Genfit S.A.
EYEN	Eyenovia, Inc.
TNYA	Tenaya Therapeutics, Inc.
INZY	Inozyme Pharma, Inc.